MKI-1, a Novel Small-Molecule Inhibitor of MASTL, Exerts Antitumor and Radiosensitizer Activities Through PP2A Activation in Breast Cancer
Ah Young Kim(Korea Institute of Radiological and Medical Sciences), Jae‐Sung Kim(Korea Institute of Radiological and Medical Sciences)
Cited by 24
Related Papers
ERp57 modulates STAT3 activity in radioresistant laryngeal cancer cells and serves as a prognostic marker for laryngeal cancer
|Oncotarget|2015|72
miR-550a-3-5p acts as a tumor suppressor and reverses BRAF inhibitor resistance through the direct targeting of YAP
|Cell Death and Disease|2018|40
MASTL inhibition promotes mitotic catastrophe through PP2A activation to inhibit cancer growth and radioresistance in breast cancer cells
|BMC Cancer|2018|40
Inhibition of CD82 improves colitis by increasing NLRP3 deubiquitination by BRCC3
|Cellular and Molecular Immunology|2023|22